Everence Capital Management Inc. maintained its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the second quarter, according to its most recent disclosure with the SEC. The fund owned 4,425 shares of the biopharmaceutical company’s stock at the end of the second quarter. Everence Capital Management Inc.’s holdings in Alexion Pharmaceuticals were worth $538,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of ALXN. Guardian Life Insurance Co. of America boosted its stake in Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in Alexion Pharmaceuticals during the first quarter worth approximately $111,000. Independent Portfolio Consultants Inc. boosted its stake in Alexion Pharmaceuticals by 46.9% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,065 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 340 shares during the last quarter. Huntington National Bank boosted its stake in Alexion Pharmaceuticals by 1,084.6% in the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 987 shares during the last quarter. Finally, FUKOKU MUTUAL LIFE INSURANCE Co boosted its stake in Alexion Pharmaceuticals by 10.0% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,100 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 90.74% of the company’s stock.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 133.40 on Monday. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $145.41. The company has a market capitalization of $29.77 billion, a P/E ratio of 57.85 and a beta of 1.41. The stock’s 50 day moving average is $130.85 and its 200 day moving average is $123.13.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.48. The company had revenue of $912 million during the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm’s revenue for the quarter was up 21.1% on a year-over-year basis. During the same period in the prior year, the business posted $1.13 earnings per share. On average, equities analysts predict that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current fiscal year.
ALXN has been the topic of a number of recent analyst reports. TheStreet upgraded shares of Alexion Pharmaceuticals from a “c” rating to a “b-” rating in a report on Friday, July 14th. Deutsche Bank AG cut their price target on shares of Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating on the stock in a report on Thursday, May 25th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $158.00 price target on shares of Alexion Pharmaceuticals in a report on Wednesday, May 24th. Leerink Swann restated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 23rd. Finally, Stifel Nicolaus restated a “buy” rating and set a $157.00 price objective on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Six research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $156.13.
In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 700 shares of the company’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the transaction, the director now directly owns 6,315 shares in the company, valued at $869,828.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bros. Advisors Lp Baker acquired 1,348,955 shares of Alexion Pharmaceuticals stock in a transaction on Wednesday, June 14th. The shares were bought at an average price of $116.32 per share, with a total value of $156,910,445.60. The disclosure for this purchase can be found here. Insiders have acquired 2,019,734 shares of company stock valued at $235,606,846 over the last 90 days. 4.35% of the stock is currently owned by company insiders.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.